相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cissampelos pareira L.: A review of its traditional uses, phytochemistry, and pharmacology
Surekha Kumari et al.
JOURNAL OF ETHNOPHARMACOLOGY (2021)
Rap1-GTPases control mTORC1 activity by coordinating lysosome organization with amino acid availability
Anders P. Mutvei et al.
NATURE COMMUNICATIONS (2020)
Traditional Ayurvedic and herbal remedies for Alzheimer's disease: from bench to bedside
Rohit Sharma et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2019)
Properties of FDA-approved small molecule protein kinase inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Architecture of human Rag GTPase heterodimers and their complex with mTORC1
Madhanagopal Anandapadamanaban et al.
SCIENCE (2019)
mTORC1 Overactivation as a Key Aging Factor in the Progression to Type 2 Diabetes Mellitus
Carlos Guillen et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
mTOR signalling and cellular metabolism are mutual determinants in cancer
Dirk Mossmann et al.
NATURE REVIEWS CANCER (2018)
p38 inhibition provides anti-DNA virus immunity by regulation of USP21 phosphorylation and STING activation
Yunfei Chen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Crystal structure of the human lysosomal mTORC1 scaffold complex and its impact on signaling
Mariana E. G. de Araujo et al.
SCIENCE (2017)
Secondary Metabolites from Cissampelos, A Possible Source for New Leads with Anti- Inflammatory Activity
Mateus F. Alves et al.
CURRENT MEDICINAL CHEMISTRY (2017)
mTOR Signaling in Growth, Metabolism, and Disease (vol 168, pg 960, 2017)
Robert A. Saxton et al.
CELL (2017)
Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: Pathogenesis and therapeutic options
Robert E. Brown et al.
ONCOTARGET (2016)
Discovering new mTOR inhibitors for cancer treatment through virtual screening methods and in vitro assays
Ling Wang et al.
SCIENTIFIC REPORTS (2016)
A Phase I Dose-Escalation Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the Dual mTORC1/mTORC2 Kinase Inhibitor CC-223 in Patients With Advanced Solid Tumors or Multiple Myeloma
Johanna C. Bendell et al.
CANCER (2015)
Cancer stem cells and cell size: A causal link?
Qiuhui Li et al.
SEMINARS IN CANCER BIOLOGY (2015)
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma
Elisa Zanardi et al.
THERAPEUTIC ADVANCES IN UROLOGY (2015)
ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers
Brian G. Pierce et al.
BIOINFORMATICS (2014)
Rapalogs and mTOR inhibitors as anti-aging therapeutics
Dudley W. Lamming et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
mTOR kinase structure, mechanism and regulation
Haijuan Yang et al.
NATURE (2013)
[11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers
Min Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
mTOR Inhibitors in Tuberous Sclerosis Complex
Paolo Curatolo et al.
Current Neuropharmacology (2012)
PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity
Jing Yuan et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Shripad V. Bhagwat et al.
MOLECULAR CANCER THERAPEUTICS (2011)
mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo
Thorsten Fuereder et al.
CANCER LETTERS (2010)
The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1
Yasemin Sancak et al.
SCIENCE (2008)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
分享论文
